AMRA Medical

Executive Summary

AMRA Medical is a Swedish digital health company specializing in advanced MRI-based body composition analytics. Founded in 2010, the company provides precise, non-invasive biomarkers of fat distribution and muscle composition, enabling more accurate phenotyping in clinical research and patient care. Its proprietary technology extracts quantitative insights from standard MRI scans, offering a more sensitive and specific alternative to traditional methods like DXA or bioimpedance. AMRA's biomarkers are increasingly adopted in pharmaceutical drug development to enhance clinical trial outcomes and support regulatory approvals, particularly in metabolic diseases, oncology, and neuromuscular disorders. The company operates at the intersection of imaging, AI, and precision medicine, positioning itself as a key enabler of data-driven clinical decisions. AMRA Medical addresses a growing market demand for digital biomarkers that improve trial efficiency and patient stratification. The company's platform has been validated in multiple studies and is used by leading pharmaceutical firms and academic institutions. With the global digital biomarker market expected to expand rapidly, AMRA is well-positioned to capture a significant share through further commercial partnerships and regulatory clearances. Recent developments include expanded collaborations and potential CE marking for new applications. As the industry moves toward more personalized approaches, AMRA's technology offers a scalable solution for routine clinical use. Despite being privately held, the company's strong scientific foundation and strategic focus suggest robust growth prospects in the near term.

Upcoming Catalysts (preview)

• Q3 2026Major Pharma Partnership for Late-Stage Trial60% success
• Q1 2027FDA 510(k) Clearance for New Biomarker Application50% success
• Q4 2026Publication of Pivotal Validation Study in High-Impact Journal70% success